Clinical significance of serum GP73, AFP, and CA199 test in the diagnosis of hepatic cancer
-
摘要:
目的 探讨血清高尔基体蛋白73 (GP73) 及其与甲胎蛋白(AFP) 和CA199联合检测对原发性肝癌(PHC) 诊断的价值。 方法 收集肝癌患者50例、肝炎患者20例、肝硬化患者20例、除肝癌外其他消化系统恶性肿瘤患者20例及健康对照者20例。用酶联免疫分析方法定量检测各组人群血清GP73, 用电化学发光法测定AFP和CA199。 结果 肝癌组血清GP73含量中位数(104.4μg/L) 明显高于肝炎组(22.7μg/L)、肝硬化组(53.8μg/L)、其他消化系统肿瘤组(41.4μg/L) 和对照组(19.3μg/L), P均 < 0.05。单项指标中GP73用于肝癌诊断的灵敏度、特异性和准确率均最高, 分别为72.0%、95.0%和86.2%, GP73/AFP/CA199平行实验灵敏度最高(92.0%), GP73+AFP+CA199系列实验特异性最高(100%), GP73/AFP平行实验准确率最高(87.7%)。ROC曲线分析GP73曲线下面积最大, 为0.824。三个检测指标之间相关性分析无统计学意义(P > 0.05)。 结论 GP73是一种新的更有效的肝癌诊断的血清标志物, 其联合AFP和CA199检测可提高对PHC的诊断价值。 Abstract:Objective To investigate the clinical value of serum Glogi glycoprotein 73 (GP73) and its combination to alpha-fetoprotein (AFP) and CA199 for the diagnosis of primary hepatic cancer (PHC). Methods Sera from 110 patients (50 hepatic cancer, 20 hepatitis, 20 liver cirrhosis, and 20 malignant tumors of the digestive system except hepatic cancer) and 20 healthy controls were collected.Serum GP73 was analyzed by enzyme-1inked immunosorbent assay.The levels of AFP and CA199 were quantified by electrochemiluminescence immunoassays. Results The median serum GP73 concentration of PHC (104.4 μg/L) was higher than that of hepatitis (22.7 μg/L), liver cirrhosis (53.8 μg/L), malignant tumors of the digestive system except hepatic cancer (41.4 μg/L), and healthy controls (19.3 μg/L) significantly (P < 0.05).The sensitivity, specificity, and accuracy to diagnose PHC by GP73 alone were 72.0%, 95.0% and 86.2%, respectively, and were higher than that of AFP or CA199 alone.GP73's sensitivity was highest (92.0%) for the parallel test of GP73, AFP, and CA199;its specificity was highest (100.0%) for the series-wound test of GP73, AFP, and CA199;and its accuracy was the highest (87.7%) for the parallel test of GP73 and AFP.The area under the ROC curve of GP73 was 0.824, which is higher than that of AFP or CA199 alone.The serum GP73 level was not significantly correlated with that of AFP or CA199. Conclusion GP73 is a new effective marker in the diagnosis of PHC, and the combined examination of GP73, AFP, and CA199 can improve the diagnosis value of PHC. -
Key words:
- primary hepatic cancer /
- glogi glycoprotein 73 /
- alpha-fetoprotein /
- CA199
-
表 1 各组血清GP73、AFP和CA199含量检测结果比较[中位数(四分位数)]
Table 1. Comparison of serum GP73, AFP, and CA199 levels in every group[median(quartile)]
表 2 各组血清GP73、AFP和CA199阳性检出率比较
Table 2. Comparison of the positive rate in every group about GP73, AFP, and CA199
表 3 血清GP73、AFP和CA199单项及联检对PHC的诊断价值比较
Table 3. Comparison of the diagnosis value about single and combined examination of GP73, AFP, and CA199 for PHC
-
[1] Gomaa AI, Khan SA, Leen EL, et al. Diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2009, 15 (11): 1301-1314. doi: 10.3748/wjg.15.1301 [2] 徐海峰, 杨华瑜, 张宏冰, 等. 改变肝癌早期诊断和治疗现状的新肝癌血清标志物[J]. 基础医学与临床, 2008, 28 (1): 104-108. https://www.cnki.com.cn/Article/CJFDTOTAL-JCYL200801042.htm [3] Zhao XY, Li N, Ding HG, et al. Detection and evaluation of serum GP73, a resident Golgi glycoprotein, as a marker in diagnosis of he patocellular carcinoma[J]. Zhong Hua Zhong Liu Za Zhi, 2010, 32 (12): 943-945. [4] Mao Y, Yang H, Xu H, et al. Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59 (12): 1687-1693. doi: 10.1136/gut.2010.214916 [5] 李利军, 李新丰, 王高雄. GP73联合AFP、VEGF检测对原发性肝癌的诊断价值[J]. 世界华人消化杂志, 2009, 17 (29): 3056-3060. doi: 10.3969/j.issn.1009-3079.2009.29.018 [6] 王向臣, 曲建香, 鹿理友, 等. AFP、AFP-L3、GP73联合检测在肝癌诊断中的应用[J]. 医学检验与临床, 2011, 22 (6): 50-52. https://www.cnki.com.cn/Article/CJFDTOTAL-JYYL201701008.htm [7] Block TM, Comunale MA, Lowman M, et al. Use of target glyco proteomica to identify serum glycoproteins that correlate with liver cancer in woodchucks and humand[J]. Proc Natl Acad Sci U S A, 2005, 102 (3): 779-784. doi: 10.1073/pnas.0408928102 [8] Drake RR, Schwegler EE, Malik G, et al. Lectin capture strategies combined wiith mass spectrometry for the discovery of serum glyco protein biomarkers[J]. Mol Cell Proteomics, 2006, 5 (10): 1957-1967. doi: 10.1074/mcp.M600176-MCP200 [9] Zhou Y, Yin X, Ying J, et al. Golgi protein 73 versus alpha-feto protein as a biomarker for hepatocellular carcinoma: a diagnostic meta-analysis[J]. BMC Cancer, 2012, 12 (1): 17. doi: 10.1186/1471-2407-12-17 [10] Ozkan H, Erdal H, Tutkak H, et al. Diagnostic and prognostic va lidity of Golgi protein 73 in hepatocellular carcinoma[J]. Digestion, 2011, 83 (1-2): 83-88. doi: 10.1159/000320379 [11] 许文芳, 费迎明, 周建康, 等. 血清GP73、AFP和AFP-L3联合检测在原发性肝癌诊断中的价值[J]. 中华实验和临床病毒学杂志, 2011, 25 (4): 286-288. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSZD201510011.htm [12] Tian L, Wang Y, Xu D, et al. Serological AFP/golgi protein 73 could be a new diagnostic parameter of hepatic diseases[J]. Int J Cancer, 2011, 129 (8): 1923-1931. doi: 10.1002/ijc.25838 [13] Hu JS, Wu DW, Liang S, et al. GP73, a resident Golgi glycopro tein, is sensibility and specificity for hepatocellular carcinoma of di agnosis in a hepatitis B-endemic Asian population[J]. Med Oncol, 2010, 27 (2): 339-345. doi: 10.1007/s12032-009-9215-y [14] Liu X, Wan X, Li Z, et al. Golgi protein 73 (GP73), a useful serum marker in liver diseases[J]. Clin Chem Lab Med, 2011, 49 (8): 1311-1316. [15] Morota K, Nakagawa M, Sekiya R, et al. A comparative evaluation of Golgi protein-73, fucosylated hemopexin, α-fetoprotein, and PIVKA-II in the serum of patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma[J]. Clin Chem Lab Med, 2011, 49 (4): 711-718. [16] 徐万菊, 赵莉, 马万山. 甲胎蛋白异质体与高尔基体蛋白73在肝细胞癌诊断中的应用进展及展望[J]. 医学检验与临床, 2009, 20 (6): 71-75.